View Older Stories View More Recent Stories
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
SRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) Following Expert Call
-
TOP RANKED ROSEN LAW FIRM Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
SRPT INVESTOR ALERT: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
SRPT SECURITIES ALERT: Sarepta Therapeutics, Inc. Investors are Notified to Contact BFA Law about its Pending Securities Fraud Investigation
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
FDA investigating deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients following elevidys
-
Sarepta Therapeutics, Inc. Investors are Notified to Contact BFA Law to Potentially Recover Losses in Securities Fraud Investigation
-
SAREPTA FRAUD: BFA Law Reminds Sarepta Therapeutics, Inc. (SRPT) Investors with Losses to Contact the Firm about the Securities Fraud Investigation
-
Piper Sandler Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
SRPT FRAUD NOTICE: Sarepta Therapeutics, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law about the Securities Fraud Investigation
-
Sarepta Therapeutics (SRPT) PT Lowered to $45 at Oppenheimer
-
William Blair Downgrades Sarepta Therapeutics (SRPT) to Market Perform
-
SRPT INQUIRY ALERT: Investors of Sarepta Therapeutics, Inc. that Lost Money are Notified to Contact BFA Law about Ongoing Investigation after Elevidys Death
-
SRPT NOTIFICATION: Sarepta Therapeutics, Inc. Investors are Notified to Contact BFA Law about Securities Fraud Investigation after Elevidys Death
-
Sarepta Therapeutics (SRPT) PT Lowered to $40 at Mizuho
-
TD Cowen Downgrades Sarepta Therapeutics (SRPT) to Hold
-
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI
-
SRPT INVESTIGATION: BFA Law Notifies Sarepta Therapeutics, Inc. Investors to Contact the Firm after Second Elevidys Death Triggers Securities Fraud Investigation
-
SRPT Alert: Kehoe Law Firm, P.C. Investigating Potential Securities Fraud Claims on Behalf of Investors of Sarepta Therapeutics, Inc
-
Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral
-
Wolfe Research Starts Sarepta Therapeutics (SRPT) at Peerperform
-
Sarepta Therapeutics (SRPT) PT Lowered to $62 at TD Cowen
-
Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
-
Sarepta Therapeutics (SRPT) call put ratio 2.1 calls to 1 put with a focus on August 60 and 70 calls as share price down 43%
-
BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
-
BofA Securities Downgrades Sarepta Therapeutics (SRPT) to Neutral
-
UBS Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta shares under pressure, analysts flag risks after second Elevidys-linked death
-
Sarepta Therapeutics (SRPT) Provides Safety Update for ELEVIDYS
-
H.C. Wainwright Downgrades Sarepta Therapeutics (SRPT) to Sell
-
Stocks expected to have increasing option volume: SRPT CCL SATS X
-
Sarepta Therapeutics (SRPT) 30-day option implied volatility is at 74 into share price lower before the bell
-
BMO Capital Downgrades Sarepta Therapeutics (SRPT) to Market Perform
-
Piper Sandler Downgrades Sarepta Therapeutics (SRPT) to Neutral
-
Scotiabank Upgrades Sarepta Therapeutics (SRPT) to Sector Outperform, 'Attractive Risk Reward Ahead of Important Catalysts'
-
Regenxbio DMD data should have no impact on Sarepta Therapeutics (SRPT), especially at this price - BMO Capital
-
Sarepta Therapeutics (SRPT) Granted FDA Platform Technology Designation to the Viral Vector Used in SRP-9003
-
Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary'
